Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
Sponsor: AstraZeneca
Summary
This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)
Official title: A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN)
Key Details
Gender
All
Age Range
18 Years - 130 Years
Study Type
INTERVENTIONAL
Enrollment
175
Start Date
2018-12-27
Completion Date
2026-03-26
Last Updated
2026-02-11
Healthy Volunteers
No
Interventions
Durvalumab
Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1
Danvatirsen
Danvatirsen IV Loading dose Cycle 1 Day 1, Cycle 1 Day 3, and Cycle 1 Day 5 then once a week (q1w) starting at Cycle 1 Day 8
Oleclumab
Oleclumab IV Cohort A: Every 2 weeks (q2w) for first 2 cycles, then every 4 weeks (q4w) starting at Cycle 3 Day 1 Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1
MEDI5752
MEDI5752 IV Every 3 weeks (q3w)
Pemetrexed
Pemetrexed IV Day 1 of each 21-day cycle Arm B1: Day 1 of each 21-day cycle for the first 4 cycles then either every 3 weeks (q3w) or every 4 weeks (q4w) (per investigator discretion) thereafter Arm B2 and B3: Day 1 of each 21-day cycle for the first 4 cycles then Day 1 of each 28-day cycle (q4w) thereafter Arm B5: Day 1 of each 21-day cycle throughout the study
Carboplatin
Carboplatin IV Day 1 of each 21-day cycle
Gemcitabine
Gemcitabine IV Days 1 and 8 of each 21-day cycle
Cisplatin
Cisplatin IV Day 1 of each 21-day cycle
Nab-paclitaxel
Nab-paclitaxel IV Days 1, 8, and 15 of each 21-day cycle
AZD2936
AZD2936 IV
Locations (41)
Research Site
Iowa City, Iowa, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Nashville, Tennessee, United States
Research Site
Salzburg, Austria
Research Site
Vienna, Austria
Research Site
Edegem, Belgium
Research Site
Bialystok, Poland
Research Site
Bydgoszcz, Poland
Research Site
Gdansk, Poland
Research Site
Grudziądz, Poland
Research Site
Lodz, Poland
Research Site
Olsztyn, Poland
Research Site
Tomaszów Mazowiecki, Poland
Research Site
Warsaw, Poland
Research Site
Wroclaw, Poland
Research Site
Krasnoyarsk, Russia
Research Site
Moscow, Russia
Research Site
Saint Petersburg, Russia
Research Site
Saint Petersburg, Russia
Research Site
Cheongju-si, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Barcelona, Spain
Research Site
Barcelona, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Research Site
Seville, Spain
Research Site
Kaohsiung City, Taiwan
Research Site
Taichung, Taiwan
Research Site
Taichung, Taiwan
Research Site
Tainan, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taoyuan District, Taiwan
Research Site
Bangkok, Thailand
Research Site
Bangkok, Thailand
Research Site
Chiang Mai, Thailand
Research Site
Hat Yai, Thailand